Brophy Wealth Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 7,323 shares of the company's stock, valued at approximately $1,431,000.
Other hedge funds also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Dunhill Financial LLC increased its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP increased its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 92.80% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have commented on ZTS shares. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, August 14th. Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Wednesday, September 18th. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday. They set a "neutral" rating and a $196.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $216.70.
Check Out Our Latest Research Report on ZTS
Zoetis Stock Performance
Shares of NYSE:ZTS traded down $1.44 during midday trading on Tuesday, reaching $176.71. The company had a trading volume of 1,646,209 shares, compared to its average volume of 2,541,524. The company's 50 day moving average price is $181.72 and its 200 day moving average price is $181.12. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market cap of $79.73 billion, a P/E ratio of 33.22, a P/E/G ratio of 2.88 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.
Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date was Thursday, October 31st. Zoetis's dividend payout ratio is currently 32.52%.
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
